AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
0.912
-0.038 (-4.00%)
Jan 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.90 - 0.95
52 week 0.61 - 1.96
Open 0.95
Vol / Avg. 127,369.00/537,744.00
Mkt cap 48.08M
P/E     -
Div/yield     -
EPS -1.08
Shares 52.26M
Beta 1.03
Inst. own 32%
Jan 15, 2015
Aveo Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Nov 24, 2014
Aveo Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1653.61% -8277.57%
Operating margin -1615.01% -8035.89%
EBITD margin - -7121.96%
Return on average assets -60.80% -60.50%
Return on average equity -142.57% -113.33%
Employees 71 -
CDP Score - -

Address

650 E. KENDALL STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, is a biopharmaceutical company. The Company is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors, and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite.

Officers and directors

Tuan Ha-Ngoc Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Joseph Vittiglio Senior Vice President, General Counsel
Age: 42
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 69
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Robert C. Young M.D Independent Director
Age: 74
Bio & Compensation  - Reuters